Class action lawsuit brought by Eiger BioPharmaceuticals: Johnson fistula

Class action lawsuit brought by Eiger BioPharmaceuticals: Johnson fistula


SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) — The shareholder rights law firm Johnson Fistel, LLP ( examines whether Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), one of its officers or others has violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors’ losses and whether they can be recovered under federal securities laws.

What if I bought Eiger common shares? If you bought Eiger common stock and suffered significant losses on your investment, join our investigation now:

There are no costs or obligations for you.

What does Johnson examine fistula? On September 6, 2022, Eiger provided an update on the status of its planned Emergency Use Authorization (EUA) application for peginterferon lambda. The company stated, “Following a cooperative and extensive pre-EEA exchange of information with the FDA regarding the Phase 3 TOGETHER study of peginterferon lambda for COVID-19, the agency has indicated that it is not yet in a position to determine whether the Criteria for submitting an application and being granted an EUA are likely to be met. The FDA has indicated that it will review all new information and data from the TOGETHER study to support an EUA and the company’s plans to advance peginterferon lambda for COVID-19. Eiger remains in active dialogue with the FDA and will provide the agency with additional information that the company believes could support an EUA.”

What if I have relevant non-public information? Those with nonpublic information about the company should consider cooperating with our investigation or participating in the SEC’s whistleblower program. Under the SEC program, whistleblowers who provide original information may, under certain circumstances, receive rewards totaling up to 30% for each successful recovery by the SEC. For more information contact Jim…

Continue to read on GlobeNewswire

More to explorer